Acerus Pharmaceuticals Probability of Future OTC Stock Price Finishing Over 0.019

ASPCFDelisted Stock  USD 0.22  0.00  0.00%   
Acerus Pharmaceuticals' future price is the expected price of Acerus Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Acerus Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
  
Please specify Acerus Pharmaceuticals' target price for which you would like Acerus Pharmaceuticals odds to be computed.

Acerus Pharmaceuticals Target Price Odds to finish over 0.019

The tendency of Acerus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 0.02  in 90 days
 0.22 90 days 0.02 
about 91.98
Based on a normal probability distribution, the odds of Acerus Pharmaceuticals to stay above $ 0.02  in 90 days from now is about 91.98 (This Acerus Pharmaceuticals probability density function shows the probability of Acerus OTC Stock to fall within a particular range of prices over 90 days) . Probability of Acerus Pharmaceuticals price to stay between $ 0.02  and its current price of $0.22 at the end of the 90-day period is about 19.41 .
Assuming the 90 days horizon Acerus Pharmaceuticals has a beta of -2.34. This suggests as returns on its benchmark rise, returns on holding Acerus Pharmaceuticals are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Acerus Pharmaceuticals is expected to outperform its benchmark. Additionally Acerus Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
   Acerus Pharmaceuticals Price Density   
       Price  

Predictive Modules for Acerus Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Acerus Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acerus Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.220.220.22
Details
Intrinsic
Valuation
LowRealHigh
0.210.210.24
Details
Naive
Forecast
LowNextHigh
0.280.280.28
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.220.220.22
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acerus Pharmaceuticals. Your research has to be compared to or analyzed against Acerus Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Acerus Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Acerus Pharmaceuticals.

Acerus Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Acerus Pharmaceuticals is not an exception. The market had few large corrections towards the Acerus Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Acerus Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Acerus Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-1.36
β
Beta against NYSE Composite-2.34
σ
Overall volatility
0.25
Ir
Information ratio -0.23

Acerus Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acerus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acerus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Acerus Pharmaceuticals is not yet fully synchronised with the market data
Acerus Pharmaceuticals has some characteristics of a very speculative penny stock
Acerus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company has accumulated 21.14 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. Acerus Pharmaceuticals has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Acerus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acerus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acerus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acerus to invest in growth at high rates of return. When we think about Acerus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.82 M) with profit before overhead, payroll, taxes, and interest of 1 M.
Acerus Pharmaceuticals has accumulated about 1.29 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Roughly 91.0% of Acerus Pharmaceuticals shares are held by company insiders

Acerus Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acerus OTC Stock often depends not only on the future outlook of the current and potential Acerus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acerus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.5 B

Acerus Pharmaceuticals Technical Analysis

Acerus Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Acerus OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Acerus Pharmaceuticals. In general, you should focus on analyzing Acerus OTC Stock price patterns and their correlations with different microeconomic environments and drivers.

Acerus Pharmaceuticals Predictive Forecast Models

Acerus Pharmaceuticals' time-series forecasting models is one of many Acerus Pharmaceuticals' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Acerus Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.

Things to note about Acerus Pharmaceuticals

Checking the ongoing alerts about Acerus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Acerus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Acerus Pharmaceuticals is not yet fully synchronised with the market data
Acerus Pharmaceuticals has some characteristics of a very speculative penny stock
Acerus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company has accumulated 21.14 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. Acerus Pharmaceuticals has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Acerus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acerus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acerus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acerus to invest in growth at high rates of return. When we think about Acerus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.82 M) with profit before overhead, payroll, taxes, and interest of 1 M.
Acerus Pharmaceuticals has accumulated about 1.29 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Roughly 91.0% of Acerus Pharmaceuticals shares are held by company insiders
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Consideration for investing in Acerus OTC Stock

If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments